Clarification needed on the effects of FLACS

Article

More research required to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

The authors of a new review in Current Opinion in Ophthalmology advocate for more research to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

FLACS may reduce endothelial cell loss, they write, but the reduction most likely occurs only in the early postoperative period. Research to date has reached varying conclusions on FLACS’ ability to reduce endothelial cell loss, the authors note. Some studies point to the reduced amount of ultrasound energy required with FLACS. Others show no difference or less cell loss with FLACS than with standard phacoemulsification 1 to 3 months postoperatively. At 6 months, however, some studies have found that cell loss is similar regardless of technique used.

Further, newer advancements in surgical technique or technology - biaxial microincision surgery, the use of ultraviolet light in light-adjustable IOLs, and newer viscous - dispersives, for instance - show cell loss rates that are similar to or better than standard phaco.

“Viscous dispersives may offer equal or increased protection of the corneal endothelium during surgery compared with viscoelastic devices currently in wide use, but further studies are required to support these results,” they add.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.